Q1 EPS Estimates for Guardant Health Decreased by Analyst

Guardant Health, Inc. (NASDAQ:GH - Free Report) - Stock analysts at Leerink Partnrs dropped their Q1 2026 earnings estimates for shares of Guardant Health in a note issued to investors on Monday, July 21st. Leerink Partnrs analyst P. Souda now anticipates that the company will post earnings of ($0.65) per share for the quarter, down from their prior forecast of ($0.64). The consensus estimate for Guardant Health's current full-year earnings is ($2.90) per share. Leerink Partnrs also issued estimates for Guardant Health's Q3 2026 earnings at ($0.64) EPS, Q4 2026 earnings at ($0.74) EPS, FY2026 earnings at ($2.73) EPS and FY2027 earnings at ($2.08) EPS.

Several other research firms also recently commented on GH. TD Securities boosted their target price on shares of Guardant Health from $56.00 to $60.00 and gave the stock a "buy" rating in a research report on Thursday, May 1st. Piper Sandler reissued an "overweight" rating and issued a $60.00 target price (up from $50.00) on shares of Guardant Health in a research report on Tuesday, May 6th. Barclays upped their price objective on shares of Guardant Health from $55.00 to $60.00 and gave the stock an "overweight" rating in a report on Thursday, May 1st. UBS Group upped their price objective on shares of Guardant Health from $65.00 to $70.00 and gave the stock a "buy" rating in a report on Thursday, May 1st. Finally, Scotiabank reaffirmed an "outperform" rating on shares of Guardant Health in a report on Monday, May 5th. Twenty investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, Guardant Health currently has an average rating of "Buy" and a consensus price target of $54.45.

Guardant Health Price Performance

Guardant Health stock traded down $1.07 during trading hours on Wednesday, hitting $44.42. The company had a trading volume of 1,439,025 shares, compared to its average volume of 1,812,888. The firm has a market capitalization of $5.50 billion, a P/E ratio of -13.10 and a beta of 1.44. The firm's fifty day moving average is $46.75 and its 200-day moving average is $44.69. Guardant Health has a fifty-two week low of $20.14 and a fifty-two week high of $53.42.

Guardant Health (NASDAQ:GH - Get Free Report) last released its quarterly earnings results on Wednesday, April 30th. The company reported ($0.49) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.57) by $0.08. The firm had revenue of $203.47 million for the quarter, compared to analyst estimates of $189.91 million. During the same quarter in the prior year, the firm earned ($0.46) EPS. The firm's revenue was up 20.8% compared to the same quarter last year.

Institutional Trading of Guardant Health

A number of hedge funds and other institutional investors have recently made changes to their positions in GH. IFP Advisors Inc raised its position in Guardant Health by 120.1% during the second quarter. IFP Advisors Inc now owns 612 shares of the company's stock worth $33,000 after acquiring an additional 334 shares in the last quarter. Signaturefd LLC increased its holdings in shares of Guardant Health by 50.5% in the second quarter. Signaturefd LLC now owns 635 shares of the company's stock valued at $33,000 after purchasing an additional 213 shares during the last quarter. SVB Wealth LLC acquired a new position in shares of Guardant Health in the first quarter valued at $54,000. NewEdge Advisors LLC increased its holdings in shares of Guardant Health by 13.5% in the fourth quarter. NewEdge Advisors LLC now owns 1,929 shares of the company's stock valued at $59,000 after purchasing an additional 230 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Guardant Health in the fourth quarter valued at $61,000. 92.60% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Guardant Health

In other Guardant Health news, CEO Amirali Talasaz sold 106,784 shares of Guardant Health stock in a transaction that occurred on Thursday, May 1st. The shares were sold at an average price of $49.01, for a total value of $5,233,483.84. Following the transaction, the chief executive officer owned 2,202,672 shares of the company's stock, valued at approximately $107,952,954.72. The trade was a 4.62% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Ian T. Clark sold 6,672 shares of Guardant Health stock in a transaction that occurred on Tuesday, June 17th. The shares were sold at an average price of $48.38, for a total transaction of $322,791.36. Following the completion of the transaction, the director directly owned 9,851 shares in the company, valued at approximately $476,591.38. The trade was a 40.38% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 342,300 shares of company stock valued at $17,082,238. 6.10% of the stock is currently owned by insiders.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.